


Next-Generation Nutraceuticals

Food and pharma convergence in disease prevention and personalized nutrition

Examples of food and pharma approaches to heart disease



Source: Next-Generation Nutraceuticals


“The discovery of ingredients with pharma-like properties, such as plant sterols that lower cholesterol, is opening up new markets for food products with added health benefits. The industry is now looking for new opportunities for value-added products to improve specific aspects of health and wellness as way to increase profit margins. The approaches of the food and pharma industries to chronic diseases such as heart disease are summarized above. While both industries are now aiming to provide products that prevent disease, treating disease remains the primary pursuit of the pharma industry...”

Identify new and emerging revenue opportunities in nutraceutical ingredients for food, drinks and pharmaceutical companies with this new report

Next-Generation Nutraceuticals

Food and pharma convergence in disease prevention and personalized nutrition

Unilever's products by functional category, 2004-2006



Source: Next-Generation Nutraceuticals

"Unilever is an innovative company, entering the market with novel food products that include new functional ingredients with increasingly pharma-like properties, such as blood pressure lowering and appetite suppression ingredients. One new ingredient, licensed from Japanese company Calpis in 2005, is a lactotripeptide (AmealPeptide) that has been proven to reduce blood pressure in clinical trials..."

Today, consumers are taking a more proactive approach to managing their health and the prevention of diet-related diseases, such as obesity, diabetes, cardiovascular and bone and joint diseases. Many of these diseases are at epidemic levels, and this combined with increasing patient power makes the prevention of these lifestyle diseases attractive markets for both the food and pharmaceutical industries to exploit.

Next-Generation Nutraceuticals is a new report published by Business Insights that provides analysis of how the food and pharmaceutical industries are becoming more aligned in their approach to consumer health. This report assesses the changing regulatory landscape in addition to how the strategies of leading ingredients, food, drinks and pharmaceutical companies are evolving in the new consumer health marketplace.

Understand how food and drinks manufacturers are applying genomic and proteomic technologies that are widely used in the pharmaceutical industry in order to create increasingly sophisticated functional food products with this new report.

Some key findings from this report...

The Cellf Assessment Kit from Sciona



Source: Next-Generation Nutraceuticals

"The leader in the field of personalized nutritional advice based on genetics is Sciona Inc. Sciona sell genetic testing kits - Cellf Assessment Kits - online and in supermarket pharmacies in the US (above). Customers receive a personalized nutrition and health assessment based on the results of the cheek swab genetic test and a completed questionnaire giving information on diet, lifestyle and family history..."

- **The functional food and drinks market was worth \$26.4bn in Europe and the US in 2005.** It continues to grow at a CAGR of 4.4%, driven by consumers' increasing acceptance of functional foods and a desire to self-medicate.
- **The food and drinks industry is adopting pharma technologies in order to create more sophisticated and personalized health products.** These technologies include genomics, transcriptomics, metabolomics and nanotechnology.
- **Labelling and health claim regulations are likely to change globally as a result of the evolution of functional food and drinks.** These changes are likely to include issues such as harmonization of regulatory guidelines and more extensive clinical trials.
- **A major growth area for Nestlé is heart health.** In 2004, of all the functional products launched by the company, only 6.5% were heart health products, but this share increased to 29.7% in 2006.

Your questions answered...

Examples of obesity drugs in development

Phase I		Phase II		Filed	
Company	Product	Company	Product	Company	Product
Predix Pharma	PRX-07034	Pfizer	CP 845598	Sanofi-Aventis	Acomplia
Naturex	Peptide YY (3-36)	Amylin	AC137		
Solvay	SLV319	Merck & Co	C-2624, MK-0364, C-5093, C-2735		
Shionogi	S2367	Arena Pharma	APJ0596		
Amgen	AMG-0711076	Alicon	Fluorsterone		
Amylin	AC162352	Nishin Kyojin Pharmaceutical	n5884		
GSK	856464	Spherix	lagatose		
GTX	Androgen receptor agonists	Alizyme/Takeda	ATL962		
Peglimmune	GT-388255	Sanofi-Aventis	SR-147776, AVE-1655		
Merckhylan Pharma	Cleoy-ectrone	Sanvier	S-16261		
		GSK	Radafaxine		
		Metabolic	AOD6604		
		Vivus	Onexa		

Source: Next-Generation Nutraceuticals

"In contrast to the limited uptake of pharmaceutical products to treat obesity, \$85bn was spent on food and drink products in the US and 5 major European markets that target obesity through 'low-in' or diet food and drinks. Sales of diet food and drink products are expected to reach \$100.5bn by 2010 as companies actively research and develop alternative ways to modify caloric intake using functional ingredients..."

- In what ways are the food and pharma industries converging?
- How are the food and pharma industries tackling the prevention of lifestyle related health problems including obesity, diabetes and cardiovascular disease?
- How are functional food and drinks evolving to have qualities associated with pharma products?
- How are food and drinks companies applying the use of pharma technologies?
- How will regulatory changes affect the future of functional foods and drinks globally?
- Which companies are the leading innovators in nutrigenomics and with whom are they partnering?

This new report will enable you to...

Recent products launched that contain TEAVIGO™

Nestlé Jive for Life Sorbet
Launched in South Africa Apr 2005

Toni Adelgaza Te (Slimming tea)
Launched in Ecuador Oct 2006



Source: Next-Generation Nutraceuticals

"TEAVIGO™ is a green tea extract (epigallocatechin gallate) that is used widely in traditional Asian medicine and is marketed by DSM as having beneficial effects such as weight control, which has been demonstrated in animals, improved oral health and as being potentially beneficial for heart health. DSM believes the future is personalized nutrition and the company is likely to be a market leader in this field..."

- **Assess changing cross-market dynamics** using this report's analysis of convergence between companies including Chr. Hansen and BASF and the pharmaceutical industry and the innovative functional ingredients that this produces.
- **Understand how nutrigenomics will revolutionize the functional food and drinks market** through enabling a more personalized approach to the management of diet and health, mirroring pharmacogenomic and personalized medicine developments in the pharmaceutical industry.
- **Identify the opportunities and threats resulting from regulatory changes regarding health claims on food and drinks in Europe, the US and Japan**, and the prospect of a closer alignment with pharmaceutical regulation in the development of the next generation of functional food and drink products.
- **Predict future food and pharma product developments** using the report's critical evaluation of recent partnering activity between leading food and drinks companies and innovative biotechnology platform developers.

Sample Information: 'Next-Generation Nutraceuticals'

Chapter 1: Food and Pharmaceutical Disease Prevention

Cardiovascular Disease Sales

Heart health, like obesity, offers attractively large and growing markets for food and drinks and pharma companies (Table 1.4). Heart health is also the US consumer's top health concern (International Food Information Council, 2006) providing a driving force for product development in both industries.

In 2005, \$84bn was spent in the US and 5 major European markets on the pharmaceutical treatment of CVD conditions. By 2010 sales are expected to rise to \$105bn. CVD product sales include some of the leading global pharmaceutical products such as the cholesterol

lowering agents (statins) Lipitor (atorvastatin, Pfizer) and Zocor (simvastatin, Merck & Co.). Leading drug classes include the statins and triglyceride reducers, the blood pressure modulating agents (anti-hypertensives) which include angiotensin II antagonists (AIIA) and calcium channel blockers (CCB), anti-thrombotics and anti-coagulants.

The cost of not treating CV disease is considerable and the American Heart Association estimates that in the US alone over \$394bn per year is spent on both direct and indirect costs of CV disease. This is one of the major drivers of continued heavy investment by the pharmaceutical industry in R&D as there are still significant opportunities to develop drugs to treat and prevent CV diseases and greater emphasis is being placed on early and more aggressive treatment in patients who are at high risk. According to PhRMA there are around 150 medicines in clinical development to treat heart disease and stroke (Figure 1.7), highlighting the high level of research activity within this field.




Table 1.4: Size of the food and drinks and pharmaceutical markets for heart health, (US\$,m), 2005-2010

	Food and drinks		Pharmaceuticals	
	2005	2010	2005	2010
France	193	251	7889	10200
Germany	361	524	7132	7803
Italy	181	250	5116	5017
Spain	119	161	3467	4262
UK	214	293	4459	1554
US	4385	5952	56228	76376
Total	5455	7433	84294	105214

Source: Next-Generation Nutraceuticals

Similarly, products for heart health are a major focus for many of the largest food companies including Nestlé, Unilever and Ajinomoto, with sales of heart health products reaching \$5.5bn in 2005. The industry uses a range of functional ingredients in its products for heart health: ingredients with pharma-like properties (e.g. plant sterols that reduce cholesterol and lactotripeptides that reduce blood pressure); and ingredients that have been demonstrated, to differing extents, to reduce the risk of coronary heart disease (omega-3, additional fruit, vegetables and fiber, antioxidants). These ingredients are being introduced into everyday foods such as bread, milk, fruit juice, yogurt and margarine to give consumers a wide choice of products aimed at improving their health.

Order this report today to find out more...

Table of Contents (contd.)

EXECUTIVE SUMMARY

CHAPTER 1: FOOD AND PHARMACEUTICAL DISEASE PREVENTION

- Summary
 - Introduction
 - The changing approach to the health burden
 - New technologies
 - Key convergent markets
 - Obesity
 - Epidemiology
 - Sales
 - Cardiovascular disease
 - Epidemiology
 - Sales
 - Diabetes
 - Epidemiology
 - Sales
 - Bone health
 - Epidemiology
 - Sales
- Conclusions

CHAPTER 2: FUNCTIONAL FOOD AND DRINKS

- Summary
- Introduction
- Functional food and drinks
 - Functional ingredients
 - Scientific evidence to support the health benefits of functional ingredients
 - Proving efficacy: pharma vs. food
 - Growth areas and product trends in the functional foods market
 - Heart health
 - Digestive health - Probiotics
 - Innovative ingredients aligning with pharma
- Personalized nutrition
- Conclusions

CHAPTER 3: TECHNOLOGIES FOR NUTRIGENOMICS

- Summary
- Introduction
- Biomic technologies in the pharma industry
- Pharma technologies in the food industry
 - Genomics
 - Genomics in personalized nutrition
 - Case study: Sciona Inc
 - Transcriptomics
 - Transcriptomics in the food industry
 - Case study: WellGen Inc.
 - Proteomics
 - Metabolomics
 - Case study: the INTERMAP study
 - Challenges to metabolomics in nutrition research
 - Growth and interest in metabolomics

- Systems Biology
- Nanotechnology delivering new ingredients
- Conclusions

CHAPTER 4: THE REGULATORY LANDSCAPE

- Summary
- Introduction
- Regulation of health claims for functional foods
 - Japan
 - United States
 - Health claims
 - Structure/function claims
 - Criticism of the FDA's approach
 - Europe
- Opportunities and threats of functional food regulation
 - The future of functional food regulation
- Regulation of personalized dietary advice
- Conclusions

CHAPTER 5: STRATEGIES OF LEADING INGREDIENT, FOOD, DRINKS AND PHARMA COMPANIES

- Summary
- Introduction
- Ingredient manufacturers
 - DSM
 - BASF
 - Chr. Hansen
 - Products
 - Research
 - Opportunities for the ingredients industry
- Food and drinks manufacturers
 - Nestlé
 - Nestlé's products
 - Research
 - The future for Nestlé
 - Unilever
 - Unilever's products
 - Research
 - The future for Unilever
 - Ajinomoto
 - Research and the future for Ajinomoto
 - Danone
 - The future for Danone
 - Coca-Cola
 - Other food and drinks manufacturers
- Pharma companies
- Future trends for the food and pharma industries
- Agribusiness
- Alliances
 - Food-pharma alliances
 - Alliances with new technology companies
 - Alliances for nutrigenomic research
- Conclusions

Table of Contents (Contd.)

CHAPTER 6: FUTURE CHALLENGES AND OPPORTUNITIES

- Summary
- Introduction
- Opportunities and market drivers
 - Consumer demand
 - Incentives
 - Opportunities in developing markets
 - New product development opportunities
 - Marketing
- Challenges
 - Scientific challenges
 - Furthering basic and applied research
 - Clinical testing of nutraceuticals
 - Defining health
 - Ethical, legal and societal concerns
 - Ethical concerns
 - Societal concerns
 - Privacy and human rights
 - Research practices in nutrigenomics
 - The regulatory framework
- Conclusions

TABLES

- Number and percentage of overweight and obese adults by country, 2005-2010 (% adult population)
- Size of the diet food and drinks market and the obesity pharmaceutical market, (US\$,m), 2005-2010
- Estimated prevalence of major cardiovascular diseases in the seven major markets, 2004
- Size of the food and drinks and pharmaceutical markets for heart health, (US\$,m), 2005-2010
- Prevalence of type-2 diabetes in the 7 major markets, 2005-11
- Size of the pharmaceutical market for diabetes, (US\$,m), 2005-2010
- Prevalence of Rheumatoid Arthritis based on population > 60 in the seven major markets (000s), 2005-2010
- Prevalence of osteoporosis in men and women over 50 across the seven major markets, 2005
- Size of the food and drinks and pharmaceutical markets for bone health, (US\$m), 2005-2010
- Functional ingredients
- Functional food ingredients (cont.)
- Examples of functional food ingredients and the scientific basis for health benefit claims
- Functional food and drink sales by value (\$m), 2005-2008
- Companies offering nutrigenetic testing and dietary advice 2006
- Genetic variations screened by the Cellf^o Assessment Kit from Sciona, 2006
- How nutrients alter gene expression
- Transcriptomics in nutritional biology and nutrigenomics
- Companies and research centres utilizing gene expression analysis for nutrigenomic applications
- FOSHU functions and functional food components

- Generic health claims currently approved by the FDA
- Regulatory opportunities and threats in the functional foods industry
- Ajinomoto products containing AmealPeptide^o launched in Japan
- Recent functional food and drinks launches
- Some functional food and drink products launched by pharma companies
- Consortia involved in the International Nutrigenomics Network
- Examples of other collaborative nutrigenomic research projects
- Biomarkers for well-being and disease risk reduction

FIGURES

- Drivers of change in the food and pharma industries
- Examples of food and pharma approaches to heart disease
- A functional food pyramid
- The role of food and pharmaceuticals in the healthcare continuum
- Examples of obesity drugs in development
- Global deaths from cardiovascular disease
- Drugs in clinical development for CV disorders
- Top US consumer health concerns, 2005
- Nutrigen IQ3 Yogurt Drink
- Right Direction Cookies
- DanaCol with Omega-3 & Plant Sterols Dairy Drink
- Calpis Aqua Nyusankin
- Calpis Interbalance L-92 Lactic Acid Bacteria Drink
- The 'omics technologies: definitions
- The 'omics technologies
- The Cellf^o Assessment Kit from Sciona
- Pro-inflammatory metabolic pathways
- Technologies used in proteomics
- 1H NMR spectrum of urine showing functional windows
- Large scale metabolomic screening of human populations: identifying outliers
- Standardized qualifying language for qualified health claims
- Structure/function claims allowed on food labeling
- Recent products launched that contain TEAVIGO^o
- Development of new probiotic cultures at Chr. Hansen
- Nestlé's products by functional category, 2004-2006
- Nestlé's functional brands (2005)
- Nestle NesVita Pro-Heart Probiotic Drink
- Unilever's products by functional category, 2004-2006
- Flora Pro-Active Blood Pressure Mini Drink
- Ajinomoto products by functional category, 2004-2006
- Calpis Ameal S Maïasa Yasai (vegetable breakfast drink)
- Danone's products by functional category, 2004-2006
- Danone Petit Danone Cheese Dessert
- Coca-Cola's products by functional category, 2004-2006
- Enviga
- Novartis' Benefiber Clear Choice! Powder and Isocal Jelly Arg Jelly Dessert
- Awareness and favorability towards personalized nutrition

FAX BACK TO: **+44 (0) 207 900 6688**

or scan and e-mail to
marketing@globalbusinessinsights.com

I would like to order the following report...

(Please use **BLOCK CAPITALS**)

Hard Copy (extra £50/€75/\$95)
Please allow 28 days for delivery

Interactivity (extra £50/€75/\$95)
Search, customize & translate content

Please select a license type:

	GB£	EUR€	US\$
<input type="checkbox"/> Single User (eCopy) <small>Access permitted for one individual only</small>	1495	2160	2875
<input type="checkbox"/> Site License <small>Access permitted for every individual based at one location</small>	2995	4330	5750
<input type="checkbox"/> Company License <small>Global access for every individual member of staff at the company</small>	5600	8100	10795

To ask a question about license types, email: marketing@globalbusinessinsights.com

Communications Feedback

Please let us know if any of the following factors influenced your purchase...

- | | |
|---|---|
| <input type="checkbox"/> Email/Fax/Postal promotion | <input type="checkbox"/> Trade Press |
| <input type="checkbox"/> Brochure | <input type="checkbox"/> My Account Manager |
| <input type="checkbox"/> Table of Contents | <input type="checkbox"/> Conference materials |
| <input type="checkbox"/> Colleague Recommendation | <input type="checkbox"/> Website/web search |

Recipient details (if different from Payor)

Title: Mr/Mrs/Ms (Please use **BLOCK CAPITALS**)

First Name: _____ Last Name: _____

Email: _____

Job Title: _____

Department: _____

Address: _____

City: _____ State/Province: _____

Country: _____ Post Code/ZIP: _____

Tel: _____ Fax: _____



Marketing Department
marketing@globalbusinessinsights.com

Code Ref: Website



www.globalbusinessinsights.com



+44 (0) 20 7551 9700



Registered Office: Business Insights Ltd, Mortimer House,
37-41 Mortimer Street, London W1T 3JH.
UK Registered Number: 05006037

Company details

Company name: _____




EU companies (except UK) must supply VAT / BTW / MOMS / MWST / IVA / FPA number:

Purchase Order Number (if required): _____

Payment method

Please indicate your preferred currency: GB£ EUR€ US\$

Total order value is _____

- I will forward a check payable to Business Insights Limited.
- Please invoice my company (please complete invoice address below)
- I would like to pay by bank transfer (email address required)
- Debit my credit/charge card:  Amex  Visa  Mastercard

Card No _____

Expiry Date ____ / ____ Signature _____

Payor details

Title: Mr/Mrs/Ms (Please use **BLOCK CAPITALS**)

First Name: _____ Last Name: _____

Email: _____

Job Title: _____

Department: _____

Address: _____

City: _____ State/Province: _____

Country: _____ Post Code/ZIP: _____

Tel: _____

Fax: _____

Sign here to confirm your order:

ORDERS WITHOUT A SIGNATURE CANNOT BE PROCESSED

By completing this form you agree that the data in the form will be used for the purpose of processing your order. We may also use your data to keep you informed of our products and services. As an international organization, Business Insights may need to process your data in countries which do not have data protection laws, or which have standards lower than the EU. Business Insights seeks to protect your personal data. You have a right to see and correct your data by writing to us. In case of queries, contact info@globalbusinessinsights.com. Please tick the relevant box(es) if you would not like Business Insights to contact you by:

Email Post Fax Phone

Occasionally, our client list is made available to other companies for carefully selected correspondence. Please check here if you do not wish to receive such correspondence by:

Email Post

This order is subject to our standard terms and conditions, a copy of which is available on request.